Chemomab Therapeutics - ADR opened at $1.35, in line with its previous close of $1.35. In the last trading session, the stock traded between $1.35 and $1.49. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Chemomab Therapeutics - ADR is now worth
$ 3.77
Resulting in a loss of
$ 96.23 (96.23%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.07 (+5.41%)
Day High
$1.49
Day Low
$1.35
Day Open
$1.35
Prev Close
$1.35
Volume
75,574
1W Return
15.69%
1M Return
1.35%
3M Return
-24.11%
6M Return
-22.24%
1Y Return
-46.70%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
2.27
PEG Ratio
-
ROE
-78.64%
ROCE
-83.07%
EPS (TTM)
$0.00
Investment Returns
1 Week
15.69%
1 Month
1.35%
3 Months
-24.11%
6 Months
-22.24%
9 Months
-9.94%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
1Oct
Chemomab amends merger deal with Scipher ahead of US move
Chemomab Therapeutics amended its merger agreement with Scipher Medicine. The amendment precedes Chemomab's planned redomiciliation to the United States. Details were disclosed in an SEC filing without specific financial figures.
Chemomab Therapeutics reported a Q2 2026 EPS of $(0.24), missing estimates by 60% and showing a 33.33% increase in losses year-over-year. Cash reserves declined to $6.7 million, though the company expects to fund operations into early 2027. The firm continues to advance its merger with Scipher Medicine, valued at $150 million pre-placement, aiming to close before year-end.
2mo ago
8Jul
Chemomab and Scipher merge to advance nebokitug in RA trial
Chemomab Therapeutics and Scipher Medicine entered a definitive merger agreement to combine in a stock transaction, aiming to advance nebokitug through a Phase 2 RA trial. The combined company, valued at $150 million, will operate as Scipher Medicine Corporation on Nasdaq.
